

## Datasheet for 200-901-AY8

# ECRG2 Antibody

### Overview

<b>Description:</b>	Anti-ECRG2 (CHICKEN) Antibody - 200-901-AY8
<b>Item No.:</b>	200-901-AY8
<b>Size:</b>	100 µg
<b>Applications:</b>	ELISA, IHC, WB
<b>Reactivity:</b>	Human, Mouse, Rat
<b>Host Species:</b>	Chicken

### Product Details

<b>Background:</b>	The esophageal cancer-susceptibility gene 2 (ECRG2), also known as SPINK7, is a novel tumor suppressor gene identified from the human esophagus. It interacts directly with metallothionein 2A and urokinase-type plasminogen activator (uPA), and downregulates the activity of uPA, leading to reduced cancer cell migration, invasion and metastasis. ECRG2 forms a complex with uPA and its receptor uPAR, modifying the dynamic association of uPAR with beta1 integrins and disrupting the Src/MAP kinase pathway that normally stimulates cell migration and invasion. ECRG2 may thus represent a novel therapeutic target for cancer.
<b>Synonyms:</b>	ECRG2 Antibody, ECG2, ECRG2, ECG2, UNQ745/PRO1474, Serine protease inhibitor Kazal-type 7, Esophagus cancer-related gene 2 protein, ECRG-2
<b>Host Species:</b>	Chicken
<b>Clonality:</b>	Polyclonal
<b>Format:</b>	IgY

### Target Details

<b>Gene Name:</b>	SPINK7
<b>Reactivity:</b>	Human, Mouse, Rat
<b>Immunogen Type:</b>	Conjugated Peptide
<b>Immunogen:</b>	Anti-ECRG2 antibody was prepared from chicken egg fractions produced by repeated immunizations with a 16 amino acid synthetic peptide near the C-terminus of human ECRG2.

**Purity/Specificity:** Anti-ECRG2 Antibody is an IgY fraction that has been affinity purified by immunoaffinity purification. ECRG2 antibody is predicted to not cross-react with other ECRG family members

**Relevant Links:**

- [UniProtKB - P58062](#)
- [GeneID - 84651](#)
- [NCBI - AAI09386](#)

## Application Details

**Tested Applications:** ELISA, IHC, WB

**Application Note:** Anti-ECRG2 Antibody has been tested for use in ELISA, Western Blotting, and Immunohistochemistry. Specific conditions for reactivity should be optimized by the end user. Expect a band at approximately 9 kDa in Western Blots of specific cell lysates and tissues.

**Assay Dilutions:** All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

**ELISA:** 1:10,000

**IHC:** 5 µg/mL

**WB:** 1 µg/mL

## Formulation

**Physical State:** Liquid (sterile filtered)

**Concentration:** 1.0mg/ml by UV absorbance at 280 nm

**Buffer:** 0.01 M Sodium Phosphate, 0.25 M Sodium Chloride, pH 7.2

**Preservative:** 0.02% (w/v) Sodium Azide

**Stabilizer:** None


## Shipping & Handling

**Shipping Condition:** Dry Ice

**Storage Condition:** Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.

**Expiration:** Expiration date is one (1) year from date of receipt.

## Images




### Immunohistochemistry

Immunohistochemistry of ECRG2.

Tissue: rat lung tissue.

Primary Antibody: ECRG2 antibody at 5 µg/mL.



### Western Blot

Western blot analysis of ECRG2.

Load: A-20 cell lysate.

Primary Antibody: ECRG2 antibody at 1 µg/mL in the (A) absence and (B) presence of blocking peptide.

## Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.